CAMBRIDGE, Mass., Feb. 15,
2017 /PRNewswire/ -- Blueprint Medicines
Corporation (NASDAQ: BPMC), a leader in discovering and
developing targeted kinase medicines for patients with genomically
defined diseases, today announced that Jeff
Albers, Blueprint Medicines' Chief Executive Officer, will
participate in a fireside chat at the 2017 RBC Capital Markets
Global Healthcare Conference on Wednesday,
February 22, 2017 at 9:30 a.m.
ET.
A live webcast of the presentation will be available by visiting
the Investors section of Blueprint Medicines' website
at http://ir.blueprintmedicines.com. A replay of the webcast
will be archived on Blueprint Medicines' website for 30
days following the presentation.
About Blueprint Medicines
Blueprint Medicines is developing a new generation of
targeted and potent kinase medicines to improve the lives of
patients with genomically defined diseases. Its approach is rooted
in a deep understanding of the genetic blueprint of cancer and
other diseases driven by the abnormal activation of
kinases. Blueprint Medicines is advancing three programs
in clinical development for subsets of patients with
gastrointestinal stromal tumors, hepatocellular carcinoma and
systemic mastocytosis, as well as multiple programs in research and
preclinical development. For more information, please visit
www.blueprintmedicines.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-2017-rbc-capital-markets-global-healthcare-conference-300405052.html
SOURCE Blueprint Medicines Corporation